Cargando…

Pharmacogenomic study on anti-VEGF medicine in treatment of macular Neovascular diseases: a study protocol for a prospective observational study

BACKGROUND: Macular neovascular diseases can cause severe vision loss. A newly approved anti—VEGF drug Conbercept has shown good efficacy and safety in rigorous random controlled trials (RCT), however, it cannot fully reflect the clinical application of Conbercept in real world clinical practice. Mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jing, Jin, Yinchen, Shen, Xia, Chen, Jing, Wang, Chong, Chen, Xun, Xu, Hengye, Huang, Kun, Liu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057085/ https://www.ncbi.nlm.nih.gov/pubmed/30041608 http://dx.doi.org/10.1186/s12886-018-0812-4

Ejemplares similares

Metabolomics study of treatment response to conbercept of patients with neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
por: Shen, Yinchen, et al.
Publicado: (2022)

Fluid dynamics between injections in incomplete anti-VEGF responders within neovascular age-related macular degeneration: a prospective observational study
por: Gigon, Anthony, et al.
Publicado: (2022)

The Architecture of Macular Neovascularizations Predicts Treatment Responses to Anti-VEGF Therapy in Neovascular AMD
por: Faatz, Henrik, et al.
Publicado: (2022)

EFEMP1 Overexpression Contributes to Neovascularization in Age-Related Macular Degeneration
por: Cheng, Lu, et al.
Publicado: (2021)

Mingjing granule, a traditional Chinese medicine in the treatment of neovascular age-related macular degeneration: study protocol for a randomized controlled trial
por: Li, Yamin, et al.
Publicado: (2021)

The Pharmacogenomics of Bipolar Disorder study (PGBD): identification of genes for lithium response in a prospective sample
por: Oedegaard, Ketil J., et al.
Publicado: (2016)

Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
por: Kaiser, Stephanie M, et al.
Publicado: (2021)

Comparing different dosing regimens of bevacizumab in the treatment of neovascular macular degeneration: study protocol for a randomised controlled trial
por: Foss, Alexander JE, et al.
Publicado: (2015)

Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration
por: Kabanarou, Stamatina A, et al.
Publicado: (2017)

Brolucizumab for persistent macular fluid in neovascular age-related macular degeneration after prior anti-VEGF treatments
por: Hussain, Rehan M., et al.
Publicado: (2021)

A computational study of VEGF production by patterned retinal epithelial cell colonies as a model for neovascular macular degeneration
por: Baker, Qanita Bani, et al.
Publicado: (2017)

A 12-month, prospective, observational study of ranibizumab in treatment-naïve Taiwanese patients with neovascular age-related macular degeneration: the RACER study
por: Wu, Wen-Chuan, et al.
Publicado: (2020)

Probabilistic Forecasting of Anti-VEGF Treatment Frequency in Neovascular Age-Related Macular Degeneration
por: Pfau, Maximilian, et al.
Publicado: (2021)

Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration
por: Wykoff, Charles C., et al.
Publicado: (2018)

Using Pharmacogenomic Testing in Primary Care: Protocol for a Pilot Randomized Controlled Study
por: Manzor Mitrzyk, Beatriz, et al.
Publicado: (2019)

The effect of vitreomacular interface in neovascular age-related macular degeneration treated with intravitreal injection of anti-VEGF
por: Han, Fangyuan, et al.
Publicado: (2022)

Korean medicine registry for low back pain – A study protocol for prospective observational multi-center study (KLOS)
por: Ko, Youme, et al.
Publicado: (2020)

Macular neovascularization in eyes with pachydrusen
por: Teo, Kelvin Yi Chong, et al.
Publicado: (2021)

Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review
por: Yang, Shiqi, et al.
Publicado: (2016)

Genetic Association Analysis of Anti-VEGF Treatment Response in Neovascular Age-Related Macular Degeneration
por: Strunz, Tobias, et al.
Publicado: (2022)

Risk factors for myopic choroidal neovascularization-related macular atrophy after anti-VEGF treatment
por: Bae, Ki Woong, et al.
Publicado: (2022)

Treatment of ankle sprain or instability in Korean medicine clinics: A protocol for a prospective multicenter observational study
por: Han, Gajin, et al.
Publicado: (2020)

The pharmacogenomics of pain management: prospects for personalized medicine
por: Ting, Sonya, et al.
Publicado: (2016)

Removal of choroidal neovascular membrane in a case of macular hole after anti-VEGF therapy for age-related macular degeneration
por: Hirata, Akira, et al.
Publicado: (2017)

Imaging Hyperreflective Foci as an Inflammatory Biomarker after Anti-VEGF Treatment in Neovascular Age-Related Macular Degeneration Patients with Optical Coherence Tomography Angiography
por: Wu, Jing, et al.
Publicado: (2021)

The Brain and Early Experience Study: Protocol for a Prospective Observational Study
por: Mills-Koonce, William Roger, et al.
Publicado: (2022)

Visual Outcomes of Anti-VEGF Treatment on Neovascular Age-Related Macular Degeneration: A Real-World Population-Based Cohort Study
por: Korva-Gurung, Ida, et al.
Publicado: (2023)

Aqueous proteins help predict the response of patients with neovascular age-related macular degeneration to anti-VEGF therapy
por: Cao, Xuan, et al.
Publicado: (2022)

Inhibition of Pathological Retinal Neovascularization by a Small Peptide Derived from Human Tissue-Type Plasminogen Kringle 2
por: Sun, Qian, et al.
Publicado: (2020)

Quality of optometry referrals to neovascular age-related macular degeneration clinic: a prospective study
por: Muen, Wisam J, et al.
Publicado: (2011)

Correlation of Baseline Visual Acuity with Outcomes of Treatment with Anti-VEGF in Neovascular Age-Related Macular Degeneration
por: Veluswamy, Balaji, et al.
Publicado: (2020)

Aqueous humour proteins and treatment outcomes of anti-VEGF therapy in neovascular age-related macular degeneration
por: Arai, Yusuke, et al.
Publicado: (2020)

Quantitative assessment of retinal fluid in neovascular age-related macular degeneration under anti-VEGF therapy
por: Reiter, Gregor S., et al.
Publicado: (2022)

Melatonin Inhibits VEGF-Induced Endothelial Progenitor Cell Angiogenesis in Neovascular Age-Related Macular Degeneration
por: Lin, Liang-Wei, et al.
Publicado: (2023)

One-Year Outcomes Using Ranibizumab for Neovascular Age-Related Macular Degeneration: Results of a Prospective and Retrospective Observational Multicentre Study
por: Hjelmqvist, Lars, et al.
Publicado: (2011)

Prospective Evaluation of Pharmacogenomics and Metabolite Measurements upon Azathioprine Therapy in Inflammatory Bowel Disease: An Observational Study
por: Fangbin, Zhang, et al.
Publicado: (2016)

Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial
por: Singerman, L J, et al.
Publicado: (2008)

Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study
por: Corazza, Paolo, et al.
Publicado: (2021)

Brolucizumab for Neovascular Age-Related Macular Degeneration (BEL Study)
por: Van Cleemput, Liesbeth, et al.
Publicado: (2023)

Prospective Outcomes of Injury Study 10 Years on (POIS-10): An Observational Cohort Study
por: Derrett, Sarah, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_338o8mkm5g8kb7p62bedvsbur2